Recombinant Protein Technical Manual

Recombinant Rat TNFSF7/CD70 Protein (His Tag)(Active)

RPES0397

Product Data:

Product SKU: RPES0397

Size: 20µg

Species: Rat

Expression host: HEK293 Cells

Uniprot: NP_001100348

Protein Information:

Molecular Mass:	18.9 kDa
AP Molecular Mass:	28 kDa
Tag:	N-His
Bio-activity:	1. Measured by its binding ability in a functional ELISA.2. Immobilized rat His-CD70 at 10µg/mL (100µL/well) can bind mouse CD27-Fch , the EC50 of mouse CD27-Fch is 10-50ng/mL.
Purity:	> 90 % as determined by SDS-PAGE
Endotoxin:	< 1.0 EU per µg of the protein as determined by the LAL method
Storage:	Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping:	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation:	Lyophilized from sterile PBS, pH 7.4
Reconstitution:	Please refer to the printed manual for detailed information.
Application:	Functional ELISA
Synonyms:	CD70

Immunogen Information:

Sequence: Gln46-Pro195

Background:

CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.